Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Antitubercular Agents"" wg kryterium: Temat


Tytuł :
Vertebral tuberculosis as a paradoxical reaction to the treatment of pulmonary and meningeal tuberculosis in an immunocompetent patient: A case report.
Autorzy :
Volpe-Chaves CE; Graduate Program in Infectious and Parasitic Diseases of Federal University of Mato Grosso do Sul.; Regional Hospital of Mato Grosso do Sul.; Maria Aparecida Pedrossian University Hospital.
Lacerda MLGG; Regional Hospital of Mato Grosso do Sul.
Castilho SB; Regional Hospital of Mato Grosso do Sul.
Fonseca SSO; Regional Hospital of Mato Grosso do Sul.
Saad BAA; Graduate Program in Infectious and Parasitic Diseases of Federal University of Mato Grosso do Sul.; Regional Hospital of Mato Grosso do Sul.
Franciscato C; Graduate Program in Infectious and Parasitic Diseases of Federal University of Mato Grosso do Sul.; Maria Aparecida Pedrossian University Hospital.
Tibana TK; Maria Aparecida Pedrossian University Hospital.
Nunes TF; Maria Aparecida Pedrossian University Hospital.
Venturini J; School of Medicine at Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.
Oliveira SMDVL; School of Medicine at Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.
Paniago AMM; School of Medicine at Federal University of Mato Grosso do Sul, Campo Grande, Mato Grosso do Sul, Brazil.
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 May 22; Vol. 99 (21), pp. e20012.
Typ publikacji :
Case Reports; Journal Article
Journal Info :
Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: Core Clinical (AIM); MEDLINE
MeSH Terms :
Antitubercular Agents/*adverse effects
Immunocompetence/*drug effects
Tuberculosis, Meningeal/*drug therapy
Tuberculosis, Pulmonary/*drug therapy
Tuberculosis, Spinal/*etiology
Adult ; Antitubercular Agents/administration & dosage ; Antitubercular Agents/therapeutic use ; Humans ; Magnetic Resonance Imaging ; Male ; Mycobacterium tuberculosis/isolation & purification ; Sacrum/diagnostic imaging ; Sacrum/pathology ; Tuberculosis, Meningeal/complications ; Tuberculosis, Pulmonary/classification ; Tuberculosis, Spinal/cerebrospinal fluid
Czasopismo naukowe
Tytuł :
Dynamic imaging in patients with tuberculosis reveals heterogeneous drug exposures in pulmonary lesions.
Autorzy :
Ordonez AA; Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Wang H; Center for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, MD, USA.
Magombedze G; Center for Infectious Diseases Research and Experimental Therapeutics, Baylor University Medical Center and Texas Tech University Health Sciences Center, Dallas, TX, USA.
Ruiz-Bedoya CA; Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Srivastava S; Center for Infectious Diseases Research and Experimental Therapeutics, Baylor University Medical Center and Texas Tech University Health Sciences Center, Dallas, TX, USA.
Chen A; Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Tucker EW; Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Urbanowski ME; Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Pieterse L; Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Fabian Cardozo E; Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Lodge MA; Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Shah MR; Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA.; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Holt DP; Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Mathews WB; Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Dannals RF; Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Gobburu JVS; Center for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, MD, USA.
Peloquin CA; Infectious Disease Pharmacokinetics Laboratory, Pharmacotherapy and Translational Research, University of Florida College of Pharmacy, Gainesville, FL, USA.
Rowe SP; Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Gumbo T; Center for Infectious Diseases Research and Experimental Therapeutics, Baylor University Medical Center and Texas Tech University Health Sciences Center, Dallas, TX, USA.
Ivaturi VD; Center for Translational Medicine, University of Maryland School of Pharmacy, Baltimore, MD, USA.
Jain SK; Center for Infection and Inflammation Imaging Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA. .; Center for Tuberculosis Research, Johns Hopkins University School of Medicine, Baltimore, MD, USA. .; Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA. .; Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. .
Pokaż więcej
Źródło :
Nature medicine [Nat Med] 2020 Apr; Vol. 26 (4), pp. 529-534. Date of Electronic Publication: 2020 Feb 17.
Typ publikacji :
Clinical Study; Journal Article; Research Support, N.I.H., Extramural
Journal Info :
Publisher: Nature Publishing Company Country of Publication: United States NLM ID: 9502015 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1546-170X (Electronic) Linking ISSN: 10788956 NLM ISO Abbreviation: Nat. Med. Subsets: MEDLINE
MeSH Terms :
Antitubercular Agents/*pharmacokinetics
Lung/*diagnostic imaging
Lung/*metabolism
Rifampin/*pharmacokinetics
Tuberculosis/*diagnosis
Tuberculosis/*drug therapy
Adult ; Animals ; Antitubercular Agents/administration & dosage ; Antitubercular Agents/blood ; Biological Availability ; Drug Therapy, Combination ; Female ; Humans ; Lung/drug effects ; Lung/pathology ; Male ; Mycobacterium tuberculosis/physiology ; Positron Emission Tomography Computed Tomography ; Rabbits ; Rifampin/administration & dosage ; Rifampin/blood ; Tissue Distribution ; Tuberculosis/metabolism ; Tuberculosis/pathology ; Tuberculosis, Pulmonary/diagnosis ; Tuberculosis, Pulmonary/drug therapy ; Tuberculosis, Pulmonary/metabolism ; Tuberculosis, Pulmonary/pathology
Czasopismo naukowe
Tytuł :
Fatty acids-carotenoid complex: An effective anti-TB agent from the chlorella growth factor-extracted spent biomass of Chlorella vulgaris.
Autorzy :
Kumar TS; Marine Biotechnology Division, National Institute of Ocean Technology, (Ministry of Earth Sciences, Government of India), Pallikaranai, Chennai, 600100, India.
Josephine A; Marine Biotechnology Division, National Institute of Ocean Technology, (Ministry of Earth Sciences, Government of India), Pallikaranai, Chennai, 600100, India.
Sreelatha T; Marine Biotechnology Division, National Institute of Ocean Technology, (Ministry of Earth Sciences, Government of India), Pallikaranai, Chennai, 600100, India.
Azger Dusthackeer VN; National Institute for Research in Tuberculosis, Chetpet, Chennai, 600031, India.
Mahizhaveni B; National Institute for Research in Tuberculosis, Chetpet, Chennai, 600031, India.
Dharani G; Marine Biotechnology Division, National Institute of Ocean Technology, (Ministry of Earth Sciences, Government of India), Pallikaranai, Chennai, 600100, India. Electronic address: .
Kirubagaran R; Marine Biotechnology Division, National Institute of Ocean Technology, (Ministry of Earth Sciences, Government of India), Pallikaranai, Chennai, 600100, India.
Raja Kumar S; Department of Marine Biotechnology, Bharathidasan University, Tiruchirapalli, 620024, India. Electronic address: .
Pokaż więcej
Źródło :
Journal of ethnopharmacology [J Ethnopharmacol] 2020 Mar 01; Vol. 249, pp. 112392. Date of Electronic Publication: 2019 Nov 15.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Elsevier Sequoia Country of Publication: Ireland NLM ID: 7903310 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7573 (Electronic) Linking ISSN: 03788741 NLM ISO Abbreviation: J Ethnopharmacol Subsets: MEDLINE
MeSH Terms :
Antitubercular Agents/*pharmacology
Carotenoids/*pharmacology
Chlorella vulgaris/*metabolism
Fatty Acids/*pharmacology
Mycobacterium tuberculosis/*drug effects
Antitubercular Agents/administration & dosage ; Antitubercular Agents/isolation & purification ; Biomass ; Carotenoids/administration & dosage ; Carotenoids/isolation & purification ; Dose-Response Relationship, Drug ; Fatty Acids/administration & dosage ; Fatty Acids/isolation & purification ; Microbial Sensitivity Tests
Czasopismo naukowe
Tytuł :
The social implications of participant choice on adherence to Isonaizid Preventive Therapy (IPT): A follow-up study to high completion rates in Eswatini.
Autorzy :
Grande SW; The Geisel School of Medicine at Dartmouth, Hanover, NH, United States of America.; University of Minnesota, School of Public Health, Minneapolis, MN, United States of America.
Adams LV; The Geisel School of Medicine at Dartmouth, Hanover, NH, United States of America.
Maseko TSB; University Research Co. LLC (URC), Mbabane, Eswatini.
Talbot EA; The Geisel School of Medicine at Dartmouth, Hanover, NH, United States of America.
deGijsel D; The Geisel School of Medicine at Dartmouth, Hanover, NH, United States of America.
Mikal J; University of Minnesota, School of Public Health, Minneapolis, MN, United States of America.
Simelane ZZ; University Research Co. LLC (URC), Mbabane, Eswatini.
Achili A; University Research Co. LLC (URC), Mbabane, Eswatini.
Mkhontfo M; University Research Co. LLC (URC), Mbabane, Eswatini.
Haumba SM; University Research Co. LLC (URC), Mbabane, Eswatini.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 May 29; Vol. 15 (5), pp. e0232841. Date of Electronic Publication: 2020 May 29 (Print Publication: 2020).
Typ publikacji :
Journal Article; Research Support, U.S. Gov't, Non-P.H.S.
Journal Info :
Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS ONE Subsets: MEDLINE
MeSH Terms :
Choice Behavior*
Patient Preference*
Antitubercular Agents/*therapeutic use
Isoniazid/*therapeutic use
Mass Drug Administration/*methods
Medication Adherence/*psychology
Medication Systems/*organization & administration
Tuberculosis/*prevention & control
Adult ; Ambulatory Care Facilities ; Antitubercular Agents/administration & dosage ; Community Health Workers ; Community-Based Participatory Research ; Comorbidity ; Eswatini/epidemiology ; Female ; Follow-Up Studies ; HIV Infections/epidemiology ; House Calls ; Humans ; Interviews as Topic ; Isoniazid/administration & dosage ; Male ; Mass Drug Administration/psychology ; Mass Screening/organization & administration ; Middle Aged ; Patient Education as Topic ; Peer Group ; Qualitative Research ; Tuberculosis/diagnosis ; Tuberculosis/epidemiology
Czasopismo naukowe
Tytuł :
Electronic medication monitor for people with tuberculosis: Implementation experience from thirty counties in China.
Autorzy :
Wang N; National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Shewade HD; International Union against Tuberculosis and Lung Disease (The Union), Paris, France.; The Union South East Asia Office, New Delhi, India.
Thekkur P; International Union against Tuberculosis and Lung Disease (The Union), Paris, France.; The Union South East Asia Office, New Delhi, India.
Huang F; National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Yuan Y; Jilin Research Institute of Tuberculosis Control, Changchun, China.
Wang X; Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China.
Wang X; The Fourth People's Hospital of Ningxia Hui Autonomous Region, Yinchuan, China.
Sun M; PATH China Program, Beijing, China.
Zhang H; National Center for Tuberculosis Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing, China.
Pokaż więcej
Źródło :
PloS one [PLoS One] 2020 Apr 29; Vol. 15 (4), pp. e0232337. Date of Electronic Publication: 2020 Apr 29 (Print Publication: 2020).
Typ publikacji :
Journal Article; Observational Study; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS ONE Subsets: MEDLINE
MeSH Terms :
Medication Adherence*
Antitubercular Agents/*therapeutic use
Tuberculosis/*drug therapy
Adolescent ; Adult ; Aged ; Antitubercular Agents/administration & dosage ; China ; Directly Observed Therapy ; Female ; Humans ; Male ; Middle Aged ; Self Administration ; Young Adult
Czasopismo naukowe
Tytuł :
Factors affecting uptake and completion of isoniazid preventive therapy among HIV-infected children at a national referral hospital, Kenya: a mixed quantitative and qualitative study.
Autorzy :
Ngugi SK; Engineer County Hospital, Nyandarua, Kenya. .
Muiruri P; Comprehensive Care Centre, Kenyatta National Hospital, Nairobi, Kenya.
Odero T; School of Nursing Sciences, University of Nairobi, Nairobi, Kenya.
Gachuno O; Department of Obstetrics and Gynaecology, School of Medicine, University of Nairobi, Nairobi, Kenya.
Pokaż więcej
Źródło :
BMC infectious diseases [BMC Infect Dis] 2020 Apr 21; Vol. 20 (1), pp. 294. Date of Electronic Publication: 2020 Apr 21.
Typ publikacji :
Journal Article
Journal Info :
Publisher: BioMed Central Country of Publication: England NLM ID: 100968551 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2334 (Electronic) Linking ISSN: 14712334 NLM ISO Abbreviation: BMC Infect. Dis. Subsets: MEDLINE
MeSH Terms :
AIDS-Related Opportunistic Infections/*drug therapy
Antitubercular Agents/*therapeutic use
Isoniazid/*therapeutic use
Latent Tuberculosis/*drug therapy
Latent Tuberculosis/*prevention & control
Adult ; Antitubercular Agents/adverse effects ; Child ; Child, Preschool ; Counseling ; Cross-Sectional Studies ; Female ; Health Personnel ; Humans ; Infant ; Isoniazid/adverse effects ; Kenya ; Male ; Middle Aged ; Patient Compliance ; Qualitative Research ; Referral and Consultation ; Retrospective Studies ; Treatment Outcome ; Treatment Refusal
Czasopismo naukowe
Tytuł :
[Advances in chemotherapy of multidrug-resistant and rifampicin-resistant tuberculosis].
Autorzy :
Liu SS
Wang LZ
Tang SJ
Pokaż więcej
Źródło :
Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases [Zhonghua Jie He He Hu Xi Za Zhi] 2020 Apr 12; Vol. 43 (4), pp. 371-375.
Typ publikacji :
Journal Article; Review
Journal Info :
Publisher: Chinese Medical Association Country of Publication: China NLM ID: 8712226 Publication Model: Print Cited Medium: Print ISSN: 1001-0939 (Print) Linking ISSN: 10010939 NLM ISO Abbreviation: Zhonghua Jie He He Hu Xi Za Zhi Subsets: MEDLINE
MeSH Terms :
Antitubercular Agents/*pharmacology
Mycobacterium tuberculosis/*drug effects
Rifampin/*pharmacology
Tuberculosis, Multidrug-Resistant/*drug therapy
Antitubercular Agents/therapeutic use ; Drug Resistance, Microbial ; Humans ; Microbial Sensitivity Tests ; Mycobacterium tuberculosis/isolation & purification ; Tuberculosis, Multidrug-Resistant/diagnosis ; Tuberculosis, Multidrug-Resistant/microbiology
Czasopismo naukowe
Tytuł :
Pyrazinamide triggers degradation of its target aspartate decarboxylase.
Autorzy :
Gopal P; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.; MSD Translational Medicine Research Centre, Merck Research Laboratories, Singapore, Singapore.
Sarathy JP; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Yee M; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Ragunathan P; School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
Shin J; School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
Bhushan S; School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
Zhu J; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.
Akopian T; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.
Kandror O; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.
Lim TK; Department of Biological Sciences, National University of Singapore, Singapore, Singapore.
Gengenbacher M; Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA.; Department of Medical Sciences, Hackensack Meridian Medical School at Seton Hall University, Nutley, NJ, USA.
Lin Q; Department of Biological Sciences, National University of Singapore, Singapore, Singapore.
Rubin EJ; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, USA.
Grüber G; School of Biological Sciences, Nanyang Technological University, Singapore, Singapore.
Dick T; Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. .; Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, USA. .; Department of Medical Sciences, Hackensack Meridian Medical School at Seton Hall University, Nutley, NJ, USA. .
Pokaż więcej
Źródło :
Nature communications [Nat Commun] 2020 Apr 03; Vol. 11 (1), pp. 1661. Date of Electronic Publication: 2020 Apr 03.
Typ publikacji :
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE
MeSH Terms :
Antitubercular Agents/*pharmacology
Carboxy-Lyases/*antagonists & inhibitors
Mycobacterium tuberculosis/*drug effects
Proteolysis/*drug effects
Pyrazinamide/*analogs & derivatives
Antitubercular Agents/therapeutic use ; Bacterial Proteins/metabolism ; Carboxy-Lyases/genetics ; Carboxy-Lyases/metabolism ; Drug Resistance, Bacterial/genetics ; Endopeptidase Clp/metabolism ; Heat-Shock Proteins/metabolism ; Humans ; Microbial Sensitivity Tests ; Mutation ; Mycobacterium tuberculosis/enzymology ; Mycobacterium tuberculosis/genetics ; Pyrazinamide/pharmacology ; Pyrazinamide/therapeutic use ; Tuberculosis/drug therapy ; Tuberculosis/microbiology
Czasopismo naukowe
Tytuł :
An iboga alkaloid chemotaxonomic marker from endemic Tabernaemontana ternifolia with antitubercular activity.
Autorzy :
Garcellano RC; Graduate School, University of Santo Tomas, Manila, Philippines.; Tiniguiban Heights, Palawan State University, Puerto Princesa City, Philippines.
Cort JR; Earth and Biological Sciences Directorate, Pacific Northwest National Laboratory, Richland, WA, USA.; Institute of Biological Chemistry, Washington State University, Pullman, WA, USA.
Moinuddin SGA; Institute of Biological Chemistry, Washington State University, Pullman, WA, USA.
Franzblau SG; Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA.
Ma R; Institute for Tuberculosis Research, College of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA.
Aguinaldo AM; Graduate School, University of Santo Tomas, Manila, Philippines.; Phytochemistry Laboratory, Research Center for the Natural and Applied Sciences, University of Santo Tomas, Manila, Philippines.
Pokaż więcej
Źródło :
Natural product research [Nat Prod Res] 2020 Apr; Vol. 34 (8), pp. 1175-1179. Date of Electronic Publication: 2019 Feb 17.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Taylor & Francis Health Sciences Country of Publication: England NLM ID: 101167924 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1478-6427 (Electronic) Linking ISSN: 14786419 NLM ISO Abbreviation: Nat. Prod. Res. Subsets: MEDLINE
MeSH Terms :
Antitubercular Agents/*pharmacology
Indole Alkaloids/*isolation & purification
Tabernaemontana/*chemistry
Antitubercular Agents/isolation & purification ; Classification ; Ibogaine/analogs & derivatives ; Ibogaine/isolation & purification ; Indole Alkaloids/chemistry ; Mycobacterium tuberculosis/drug effects ; Plant Leaves/anatomy & histology
Czasopismo naukowe
Tytuł :
Traditional Chinese medicine combined with western medicine for the treatment of secondary pulmonary tuberculosis: A PRISMA-compliant meta-analysis.
Autorzy :
Li X; School of Public Health, Shaanxi University of Chinese Medicine, Xianyang, P.R. China.
Li X
Liu Q
Sun N
Zhang B
Shi C
Zhang R
Pokaż więcej
Źródło :
Medicine [Medicine (Baltimore)] 2020 Apr; Vol. 99 (16), pp. e19567.
Typ publikacji :
Journal Article; Meta-Analysis; Systematic Review
Journal Info :
Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 2985248R Publication Model: Print Cited Medium: Internet ISSN: 1536-5964 (Electronic) Linking ISSN: 00257974 NLM ISO Abbreviation: Medicine (Baltimore) Subsets: Core Clinical (AIM); MEDLINE
MeSH Terms :
Antitubercular Agents/*therapeutic use
Drugs, Chinese Herbal/*therapeutic use
Tuberculosis, Pulmonary/*drug therapy
Alanine Transaminase/blood ; Antitubercular Agents/adverse effects ; CD4 Lymphocyte Count ; Drug Therapy, Combination ; Drugs, Chinese Herbal/adverse effects ; Humans ; Phytotherapy ; Platelet Count ; Randomized Controlled Trials as Topic ; Sputum/microbiology ; Treatment Outcome ; Tuberculosis, Pulmonary/diagnostic imaging ; Tuberculosis, Pulmonary/immunology ; Uric Acid/blood
Czasopismo naukowe
Tytuł :
Metabolomics describes previously unknown toxicity mechanisms of isoniazid and rifampicin.
Autorzy :
Combrink M; Human Metabolomics, North-West University (Potchefstroom Campus), Private Bag x6001, Box 269, Potchefstroom, 2531, South Africa.
Loots DT; Human Metabolomics, North-West University (Potchefstroom Campus), Private Bag x6001, Box 269, Potchefstroom, 2531, South Africa.
du Preez I; Human Metabolomics, North-West University (Potchefstroom Campus), Private Bag x6001, Box 269, Potchefstroom, 2531, South Africa. Electronic address: .
Pokaż więcej
Źródło :
Toxicology letters [Toxicol Lett] 2020 Apr 01; Vol. 322, pp. 104-110. Date of Electronic Publication: 2020 Jan 22.
Typ publikacji :
Journal Article; Review
Journal Info :
Publisher: Elsevier Country of Publication: Netherlands NLM ID: 7709027 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1879-3169 (Electronic) Linking ISSN: 03784274 NLM ISO Abbreviation: Toxicol. Lett. Subsets: MEDLINE
MeSH Terms :
Antitubercular Agents/*toxicity
Drug-Related Side Effects and Adverse Reactions/*etiology
Isoniazid/*toxicity
Metabolomics/*methods
Rifampin/*toxicity
Toxicity Tests/*methods
Animals ; Antitubercular Agents/metabolism ; Biomarkers/metabolism ; Biotransformation ; Drug-Related Side Effects and Adverse Reactions/diagnosis ; Drug-Related Side Effects and Adverse Reactions/metabolism ; Humans ; Isoniazid/metabolism ; Rifampin/metabolism ; Risk Assessment
Czasopismo naukowe
Tytuł :
Silver Nanoparticles for the Therapy of Tuberculosis.
Autorzy :
Tăbăran AF; Department of Pathology, University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, Romania.; Department of Nanomedicine, Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania.
Matea CT; Department of Nanomedicine, Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania.
Mocan T; Department of Nanomedicine, Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania.; Department of Physiology, University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Tăbăran A; Department of Public Health and Food Hygiene, University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, Romania.
Mihaiu M; Department of Public Health and Food Hygiene, University of Agricultural Sciences and Veterinary Medicine, Cluj-Napoca, Romania.
Iancu C; Department of Nanomedicine, Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania.; Third Surgery Department, University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Mocan L; Department of Nanomedicine, Regional Institute of Gastroenterology and Hepatology, Cluj-Napoca, Romania.; Department of Physiology, University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Pokaż więcej
Źródło :
International journal of nanomedicine [Int J Nanomedicine] 2020 Mar 31; Vol. 15, pp. 2231-2258. Date of Electronic Publication: 2020 Mar 31 (Print Publication: 2020).
Typ publikacji :
Journal Article; Review
Journal Info :
Publisher: DOVE Medical Press Country of Publication: New Zealand NLM ID: 101263847 Publication Model: eCollection Cited Medium: Internet ISSN: 1178-2013 (Electronic) Linking ISSN: 11769114 NLM ISO Abbreviation: Int J Nanomedicine Subsets: MEDLINE
MeSH Terms :
Antitubercular Agents/*pharmacology
Metal Nanoparticles/*therapeutic use
Silver/*pharmacology
Tuberculosis/*drug therapy
Antitubercular Agents/chemistry ; Humans ; Metal Nanoparticles/chemistry ; Mycobacterium Infections/drug therapy ; Mycobacterium tuberculosis/drug effects ; Mycobacterium tuberculosis/pathogenicity ; Silver/chemistry ; Tuberculosis, Multidrug-Resistant/drug therapy
Czasopismo naukowe
Tytuł :
Telacebec (Q203), a New Antituberculosis Agent.
Autorzy :
de Jager VR; TASK Applied Science, Cape Town, South Africa .
Dawson R; University of Cape Town Lung Institute, Cape Town, South Africa.
van Niekerk C; Qurient, Seongnam, South Korea.
Hutchings J; Qurient, Seongnam, South Korea.
Kim J; Qurient, Seongnam, South Korea.
Vanker N; TASK Laboratory, Cape Town, South Africa.
van der Merwe L; TASK Applied Science, Cape Town, South Africa.
Choi J; Qurient, Seongnam, South Korea.
Nam K; Qurient, Seongnam, South Korea.
Diacon AH; Stellenbosch University, Cape Town, South Africa.
Pokaż więcej
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Mar 26; Vol. 382 (13), pp. 1280-1281.
Typ publikacji :
Clinical Trial, Phase II; Letter; Randomized Controlled Trial
Journal Info :
Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N. Engl. J. Med. Subsets: Core Clinical (AIM); MEDLINE
MeSH Terms :
Antitubercular Agents/*administration & dosage
Imidazoles/*administration & dosage
Mycobacterium tuberculosis/*drug effects
Piperidines/*administration & dosage
Pyridines/*administration & dosage
Tuberculosis, Pulmonary/*drug therapy
Administration, Oral ; Antitubercular Agents/adverse effects ; Dose-Response Relationship, Drug ; Drug Therapy, Combination ; Ethambutol/administration & dosage ; Humans ; Imidazoles/adverse effects ; Isoniazid/administration & dosage ; Piperidines/adverse effects ; Pyrazinamide/administration & dosage ; Pyridines/adverse effects ; Rifampin/administration & dosage
Raport
Tytuł :
Drug-Induced Liver Injury from Anti-Tuberculosis Treatment: A Retrospective Cohort Study.
Autorzy :
Zhao H; Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland).
Wang Y; Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland).
Zhang T; Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland).
Wang Q; Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland).
Xie W; Liver Diseases Center, Beijing Ditan Hospital, Capital Medical University, Beijing, China (mainland).
Pokaż więcej
Źródło :
Medical science monitor : international medical journal of experimental and clinical research [Med Sci Monit] 2020 Mar 07; Vol. 26, pp. e920350. Date of Electronic Publication: 2020 Mar 07.
Typ publikacji :
Journal Article
Journal Info :
Publisher: International Scientific Information, Inc Country of Publication: United States NLM ID: 9609063 Publication Model: Electronic Cited Medium: Internet ISSN: 1643-3750 (Electronic) Linking ISSN: 12341010 NLM ISO Abbreviation: Med. Sci. Monit. Subsets: MEDLINE
MeSH Terms :
Antitubercular Agents/*adverse effects
Chemical and Drug Induced Liver Injury/*epidemiology
Adult ; Antitubercular Agents/therapeutic use ; Female ; Humans ; Isoniazid/adverse effects ; Isoniazid/therapeutic use ; Male ; Middle Aged ; Pyrazinamide/adverse effects ; Pyrazinamide/therapeutic use ; Retrospective Studies ; Rifampin/adverse effects ; Rifampin/therapeutic use ; Risk Factors ; Tuberculosis/drug therapy ; Young Adult
Czasopismo naukowe
Tytuł :
Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
Autorzy :
Conradie F; From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) - all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London.
Diacon AH; From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) - all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London.
Ngubane N; From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) - all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London.
Howell P; From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) - all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London.
Everitt D; From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) - all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London.
Crook AM; From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) - all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London.
Mendel CM; From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) - all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London.
Egizi E; From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) - all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London.
Moreira J; From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) - all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London.
Timm J; From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) - all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London.
McHugh TD; From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) - all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London.
Wills GH; From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) - all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London.
Bateson A; From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) - all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London.
Hunt R; From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) - all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London.
Van Niekerk C; From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) - all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London.
Li M; From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) - all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London.
Olugbosi M; From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) - all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London.
Spigelman M; From the Clinical HIV Research Unit, Faculty of Health Sciences, University of Witwatersrand, Johannesburg (F.C., N.N., P.H.), Sizwe Tropical Disease Hospital, Sandringham (F.C., P.H.), Task Applied Science and Stellenbosch University, Cape Town (A.H.D.), King DiniZulu Hospital Complex, Durban (N.N.), and the TB Alliance, Pretoria (C.V.N., M.O.) - all in South Africa; the TB Alliance, New York (D.E., C.M.M., E.E., J.M., J.T., M.L., M.S.); and the MRC Clinical Trials Unit at UCL (A.M.C., G.H.W.) and the UCL Centre for Clinical Microbiology (T.D.M., A.B., R.H.), University College London, London.
Pokaż więcej
Corporate Authors :
Nix-TB Trial Team
Źródło :
The New England journal of medicine [N Engl J Med] 2020 Mar 05; Vol. 382 (10), pp. 893-902.
Typ publikacji :
Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Massachusetts Medical Society Country of Publication: United States NLM ID: 0255562 Publication Model: Print Cited Medium: Internet ISSN: 1533-4406 (Electronic) Linking ISSN: 00284793 NLM ISO Abbreviation: N. Engl. J. Med. Subsets: Core Clinical (AIM); MEDLINE
MeSH Terms :
Antitubercular Agents/*administration & dosage
Diarylquinolines/*administration & dosage
Extensively Drug-Resistant Tuberculosis/*drug therapy
Linezolid/*administration & dosage
Nitroimidazoles/*administration & dosage
Administration, Oral ; Adolescent ; Adult ; Antitubercular Agents/adverse effects ; Bacterial Load ; Diarylquinolines/adverse effects ; Drug Therapy, Combination ; Extensively Drug-Resistant Tuberculosis/mortality ; Female ; Humans ; Intention to Treat Analysis ; Linezolid/adverse effects ; Male ; Middle Aged ; Mycobacterium tuberculosis/isolation & purification ; Nitroimidazoles/adverse effects ; Treatment Outcome ; Tuberculosis, Multidrug-Resistant/drug therapy ; Tuberculosis, Pulmonary/drug therapy ; Young Adult
Czasopismo naukowe
Tytuł :
Precision and personalized medicine and anti-TB treatment: Is TDM feasible for programmatic use?
Autorzy :
Alffenaar JC; Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2006, Australia; Westmead Hospital, Westmead, NSW 2145, Australia; Marie Bashir Institute for Infectious Diseases and Biosecurity, The University of Sydney, Camperdown, NSW 2006, Australia. Electronic address: .
Akkerman OW; University of Groningen, University Medical Center Groningen, Department of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands; University of Groningen, University Medical Center Groningen, TB Center Beatrixoord, Haren, The Netherlands.
Kim HY; Sydney Pharmacy School, Faculty of Medicine and Health, The University of Sydney, Camperdown, NSW 2006, Australia; Westmead Hospital, Westmead, NSW 2145, Australia.
Tiberi S; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; Department of Infection, Royal London and Newham Hospitals, Barts Health NHS Trust, London, United Kingdom.
Migliori GB; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; Servizio di Epidemiologia Clinica delle Malattie Respiratorie, Istituti Clinici Scientifici Maugeri IRCCS, Tradate, Italy.
Pokaż więcej
Źródło :
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases [Int J Infect Dis] 2020 Mar; Vol. 92S, pp. S5-S9. Date of Electronic Publication: 2020 Jan 26.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Elsevier Country of Publication: Canada NLM ID: 9610933 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-3511 (Electronic) Linking ISSN: 12019712 NLM ISO Abbreviation: Int. J. Infect. Dis. Subsets: MEDLINE
MeSH Terms :
Drug Monitoring*
Antitubercular Agents/*therapeutic use
Tuberculosis/*drug therapy
Antitubercular Agents/administration & dosage ; Humans ; Microbial Sensitivity Tests ; Precision Medicine ; Risk Factors
Czasopismo naukowe
Tytuł :
Adverse events in adults with latent tuberculosis infection receiving daily rifampicin or isoniazid: post-hoc safety analysis of two randomised controlled trials.
Autorzy :
Campbell JR; Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill International TB Centre, McGill University Health Centre Research Institute, McGill University, Montréal, QC, Canada; Department of Epidemiology and Biostatistics, McGill University, Montréal, QC, Canada.
Trajman A; Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill International TB Centre, McGill University Health Centre Research Institute, McGill University, Montréal, QC, Canada; Federal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Cook VJ; Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; Provincial TB Services, British Columbia Centre for Disease Control, Vancouver, BC, Canada.
Johnston JC; Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill International TB Centre, McGill University Health Centre Research Institute, McGill University, Montréal, QC, Canada; Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada; Provincial TB Services, British Columbia Centre for Disease Control, Vancouver, BC, Canada.
Adjobimey M; National Hospitalier Universitaire de Pneumo-Phtisiologie, Cotonou, Benin.
Ruslami R; Department of Biomedical Sciences, Division of Pharmacology and Therapy, Faculty of Medicine, Universitas Padjadjaran, Bandung, Indonesia.
Eisenbeis L; University of Alberta, Edmonton, AB, Canada.
Fregonese F; Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill International TB Centre, McGill University Health Centre Research Institute, McGill University, Montréal, QC, Canada.
Valiquette C; Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill International TB Centre, McGill University Health Centre Research Institute, McGill University, Montréal, QC, Canada.
Benedetti A; Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill International TB Centre, McGill University Health Centre Research Institute, McGill University, Montréal, QC, Canada; Department of Epidemiology and Biostatistics, McGill University, Montréal, QC, Canada.
Menzies D; Respiratory Epidemiology and Clinical Research Unit, Montreal Chest Institute, McGill International TB Centre, McGill University Health Centre Research Institute, McGill University, Montréal, QC, Canada; Department of Epidemiology and Biostatistics, McGill University, Montréal, QC, Canada. Electronic address: .
Pokaż więcej
Źródło :
The Lancet. Infectious diseases [Lancet Infect Dis] 2020 Mar; Vol. 20 (3), pp. 318-329. Date of Electronic Publication: 2019 Dec 19.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
Journal Info :
Publisher: Elsevier Science Country of Publication: United States NLM ID: 101130150 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1474-4457 (Electronic) Linking ISSN: 14733099 NLM ISO Abbreviation: Lancet Infect Dis Subsets: MEDLINE
MeSH Terms :
Antitubercular Agents/*adverse effects
Drug-Related Side Effects and Adverse Reactions/*epidemiology
Drug-Related Side Effects and Adverse Reactions/*pathology
Isoniazid/*adverse effects
Latent Tuberculosis/*drug therapy
Rifampin/*adverse effects
Adult ; Africa ; Americas ; Antitubercular Agents/therapeutic use ; Asia ; Australia ; Clinical Trials, Phase II as Topic ; Clinical Trials, Phase III as Topic ; Humans ; Isoniazid/therapeutic use ; Randomized Controlled Trials as Topic ; Rifampin/therapeutic use ; Risk Factors
Czasopismo naukowe
Tytuł :
Characteristics of Poor Tuberculosis Treatment Outcomes among Patients with Pulmonary Tuberculosis in Community Hospitals of Thailand.
Autorzy :
Charoensakulchai S; Phramongkutklao College of Medicine, Bangkok, Thailand.
Limsakul M; Phramongkutklao College of Medicine, Bangkok, Thailand.
Saengungsumalee I; Phramongkutklao College of Medicine, Bangkok, Thailand.
Usawachoke S; Phramongkutklao College of Medicine, Bangkok, Thailand.
Udomdech A; Phramongkutklao College of Medicine, Bangkok, Thailand.
Pongsaboripat A; Phramongkutklao College of Medicine, Bangkok, Thailand.
Kaewput W; Department of Military and Community Medicine, Phramongkutklao College of Medicine, Bangkok, Thailand.
Sakboonyarat B; Department of Military and Community Medicine, Phramongkutklao College of Medicine, Bangkok, Thailand.
Rangsin R; Department of Military and Community Medicine, Phramongkutklao College of Medicine, Bangkok, Thailand.
Suwannahitatorn P; Department of Parasitology, Phramongkutklao College of Medicine, Bangkok, Thailand.
Mungthin M; Department of Pharmacology, Phramongkutklao College of Medicine, Bangkok, Thailand.
Piyaraj P; Department of Parasitology, Phramongkutklao College of Medicine, Bangkok, Thailand.
Pokaż więcej
Źródło :
The American journal of tropical medicine and hygiene [Am J Trop Med Hyg] 2020 Mar; Vol. 102 (3), pp. 553-561.
Typ publikacji :
Journal Article
Journal Info :
Publisher: American Society of Tropical Medicine and Hygiene Country of Publication: United States NLM ID: 0370507 Publication Model: Print Cited Medium: Internet ISSN: 1476-1645 (Electronic) Linking ISSN: 00029637 NLM ISO Abbreviation: Am. J. Trop. Med. Hyg. Subsets: Core Clinical (AIM); MEDLINE
MeSH Terms :
Antitubercular Agents/*therapeutic use
Hospitals, Community/*standards
Tuberculosis, Pulmonary/*drug therapy
Tuberculosis, Pulmonary/*epidemiology
Adolescent ; Adult ; Antitubercular Agents/administration & dosage ; Cross-Sectional Studies ; Female ; Humans ; Male ; Middle Aged ; Risk Factors ; Rural Population ; Thailand ; Treatment Outcome ; Young Adult
Czasopismo naukowe
Tytuł :
Synthesis and antimycobacterial activity of thiazolidine-2,4-dione based derivatives with halogenbenzohydrazones and pyridinecarbohydrazones substituents.
Autorzy :
Trotsko N; Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Lublin, Chodzki 4A, 20-093, Lublin, Poland. Electronic address: .
Golus J; Department of Biochemistry and Biotechnology, Faculty of Pharmacy, Medical University of Lublin, Chodzki 1, 20-093, Lublin, Poland.
Kazimierczak P; Department of Biochemistry and Biotechnology, Faculty of Pharmacy, Medical University of Lublin, Chodzki 1, 20-093, Lublin, Poland.
Paneth A; Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Lublin, Chodzki 4A, 20-093, Lublin, Poland.
Przekora A; Department of Biochemistry and Biotechnology, Faculty of Pharmacy, Medical University of Lublin, Chodzki 1, 20-093, Lublin, Poland.
Ginalska G; Department of Biochemistry and Biotechnology, Faculty of Pharmacy, Medical University of Lublin, Chodzki 1, 20-093, Lublin, Poland.
Wujec M; Department of Organic Chemistry, Faculty of Pharmacy, Medical University of Lublin, Chodzki 4A, 20-093, Lublin, Poland.
Pokaż więcej
Źródło :
European journal of medicinal chemistry [Eur J Med Chem] 2020 Mar 01; Vol. 189, pp. 112045. Date of Electronic Publication: 2020 Jan 10.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 0420510 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1768-3254 (Electronic) Linking ISSN: 02235234 NLM ISO Abbreviation: Eur J Med Chem Subsets: MEDLINE
MeSH Terms :
Antitubercular Agents/*pharmacology
Hydrazones/*pharmacology
Thiazolidinediones/*pharmacology
Animals ; Antitubercular Agents/chemical synthesis ; Chlorocebus aethiops ; Drug Design ; Hydrazones/chemical synthesis ; Microbial Sensitivity Tests ; Molecular Structure ; Mycobacterium tuberculosis/drug effects ; Thiazolidinediones/chemical synthesis ; Vero Cells
Czasopismo naukowe
Tytuł :
Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania.
Autorzy :
Justine M; Center for Global Health Research, Haydom Lutheran Hospital, Haydom, Tanzania.
Yeconia A; Center for Global Health Research, Haydom Lutheran Hospital, Haydom, Tanzania.
Nicodemu I; Center for Global Health Research, Haydom Lutheran Hospital, Haydom, Tanzania.
Augustino D; Center for Global Health Research, Haydom Lutheran Hospital, Haydom, Tanzania.
Gratz J; Center for Global Health Research, Haydom Lutheran Hospital, Haydom, Tanzania.; Division of Infectious Diseases and International Health, University of Virginia, Charlottesville.
Mduma E; Center for Global Health Research, Haydom Lutheran Hospital, Haydom, Tanzania.
Heysell SK; Division of Infectious Diseases and International Health, University of Virginia, Charlottesville.
Kivuyo S; National Institute of Medical Research Muhimbili, Dar es Salaam, Tanzania.
Mfinanga S; National Institute of Medical Research Muhimbili, Dar es Salaam, Tanzania.
Peloquin CA; Infectious Disease Pharmacokinetic Laboratory, University of Florida, Gainesville.
Zagurski T; Infectious Disease Pharmacokinetic Laboratory, University of Florida, Gainesville.
Kibiki GS; East African Health Research Commission, East African Community, Arusha, Tanzania.
Mmbaga B; Kilimanjaro Clinical Research Institute, Kilimanjaro Christian Medical College, Moshi, Tanzania.
Houpt ER; Division of Infectious Diseases and International Health, University of Virginia, Charlottesville.
Thomas TA; Division of Infectious Diseases and International Health, University of Virginia, Charlottesville.
Pokaż więcej
Źródło :
Journal of the Pediatric Infectious Diseases Society [J Pediatric Infect Dis Soc] 2020 Feb 28; Vol. 9 (1), pp. 14-20.
Typ publikacji :
Journal Article
Journal Info :
Publisher: Oxford University Press Country of Publication: England NLM ID: 101586049 Publication Model: Print Cited Medium: Internet ISSN: 2048-7207 (Electronic) Linking ISSN: 20487193 NLM ISO Abbreviation: J Pediatric Infect Dis Soc Subsets: MEDLINE
MeSH Terms :
Mycobacterium tuberculosis*
Antitubercular Agents/*pharmacokinetics
Tuberculosis/*drug therapy
Adolescent ; Antitubercular Agents/administration & dosage ; Antitubercular Agents/blood ; Child ; Child, Preschool ; Drug Therapy, Combination ; Ethambutol/administration & dosage ; Ethambutol/pharmacokinetics ; Female ; HIV Seronegativity ; Humans ; Infant ; Isoniazid/administration & dosage ; Isoniazid/pharmacokinetics ; Longitudinal Studies ; Male ; Pyrazinamide/administration & dosage ; Pyrazinamide/pharmacokinetics ; Rifampin/administration & dosage ; Rifampin/pharmacokinetics ; Rural Population ; Tanzania ; Tuberculosis/blood
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies